Day One Reports First Quarter 2024 Financial Results and Corporate Progress

By Dr. Matthew Watson

OJEMDA™ (tovorafenib) launch underway following U.S. FDA accelerated approval for relapsed or refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

View post:
Day One Reports First Quarter 2024 Financial Results and Corporate Progress

Related Post

• Enterome Highlights High Complete Response Rate in Clinical Study of EO2463 for Indolent Non-Hodgkin Lymphoma at ASCO 2024 - May 25th, 2024
• Atrogi Announces Publication on Advancements in Combatting Obesity and Metabolic Complications - May 25th, 2024
• BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid... - May 25th, 2024
• Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress - May 25th, 2024
• Minutes of Annual General Meeting 2024 - May 25th, 2024
• Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit - May 25th, 2024
• Monopar Announces CFO Succession - May 25th, 2024
• Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy - May 25th, 2024
• Scilex Holding Company Sends Letter to U.S. House of Representatives on Illegal Market Manipulation of the Common Stock of Scilex Holding Company - May 25th, 2024
• IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024 - May 25th, 2024
• BioSenic provides First Quarter 2024 Business Update - May 25th, 2024
• Purespring Therapeutics presents preclinical data at the 61st ERA Congress - May 25th, 2024
• Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress - May 25th, 2024
• Sobi Receives US FDA Fast Track Designation for Emapalumab-lzsg being investigated in Macrophage Activation Syndrome - May 25th, 2024
• Scilex Holding Company Announces it has been Added to the MSCI Global Microcap Index - May 25th, 2024
• Guerbet : Hugues Lecat appointed Chairman of the Board of Directors of Guerbet. - May 25th, 2024
• OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q - May 25th, 2024
• Iovance Biotherapeutics to Present at Upcoming Conferences and Events - May 25th, 2024
• Rakovina Therapeutics Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations - May 25th, 2024
• Sobi to present new myelofibrosis data at the ASCO 2024 Annual Meeting - May 25th, 2024
• Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy... - May 17th, 2024
• Thrive Bioscience Welcomes Todd Lewis as Chief Commercial Officer - May 17th, 2024
• Faron Founders and bexmarilimab Developers Selected as Finalists for the European Inventor Award 2024 - May 17th, 2024
• Assertio to Participate in AGP Healthcare Conference on May 21 - May 17th, 2024
• Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH - May 17th, 2024
• Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives - May 17th, 2024
• Digital Utilities Ventures Completes Feed Earth Now Merger - Accelerates Growth of Regenerative Agriculture Movement - May 17th, 2024
• Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024 - May 17th, 2024
• Ventyx Biosciences to Participate in Three Upcoming Investor Conferences - May 17th, 2024
• Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference - May 17th, 2024
• New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with... - May 17th, 2024
• Harvard Bioscience, Inc. to Participate in the Benchmark Healthcare House Call Virtual Conference - May 17th, 2024
• BioSyent Releases Financial Results for Q1 2024 - May 17th, 2024
• BioSyent Declares Second Quarter 2024 Dividend - May 17th, 2024
• Lifecore Biomedical Completes Incremental Liquidity Initiatives - May 17th, 2024
• DBV Technologies Announces Results of its 2024 Combined General Meeting - May 17th, 2024
• Fortrea Appoints Machelle Sanders to Board of Directors - May 17th, 2024
• QuTEM Receives GMP Certificates and Manufacturing Permits for Transmission Electron Microscopy Laboratory from the Swedish Medical Products Agency - May 17th, 2024
• Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise - May 17th, 2024
• HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress - May 17th, 2024
• Telesis Bio Announces Reverse Stock Split - May 7th, 2024
• Shockwave Medical Reports First Quarter 2024 Financial Results - May 7th, 2024
• Aileron Therapeutics to Present at Two Upcoming Investor Conferences - May 7th, 2024
• ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates - May 7th, 2024
• Sana Biotechnology to Present at May and June 2024 Investor Conferences - May 7th, 2024
• Immuneering Recognizes Melanoma Awareness Month - May 7th, 2024
• T2 Biosystems Announces the Conversion of an Additional $15 Million of CRG Term Loan into Equity - May 7th, 2024
• Helio Genomics to Showcase Results from CLiMB Pivotal Trial in an Oral Presentation at the EASL Congress 2024 - May 7th, 2024
• T2 Biosystems Announces Commercial Expansion Through Middle East Distributor - May 7th, 2024
• Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024 - May 7th, 2024
• BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million - May 7th, 2024
• Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 7th, 2024
• T2 Biosystems Announces First Quarter 2024 Financial Results - May 7th, 2024
• argenx to Present at BofA Securities 2024 Health Care Conference - May 7th, 2024
• Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provides General Business Update - May 7th, 2024
• Sandoz reports first quarter 2024 sales - May 7th, 2024
• Memo Therapeutics increases Series C financing to CHF 45 million - May 7th, 2024
• Orion Corporation: Change in Orion Group Executive Management Board as of 31 May 2025 - May 7th, 2024
• Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates - May 7th, 2024
• Medigene AG reports Financial Results and Business Update for Q1 2024 - April 28th, 2024
• Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting - April 28th, 2024
• Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 26 April 2024 - April 28th, 2024
• Composition of the Nomination Committee of Orion Corporation - April 28th, 2024
• Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA) - April 28th, 2024
• Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024 - April 28th, 2024
• Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024 - April 28th, 2024
• Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal... - April 28th, 2024
• Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP) - April 28th, 2024
• HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda - April 28th, 2024
• Medicenna Therapeutics Announces CA$20 Million Investment from RA Capital Management - April 28th, 2024
• Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024 - April 28th, 2024
• Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments - April 28th, 2024
• UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting - April 28th, 2024
• CARBIOS celebrates the groundbreaking of its PET biorecycling plant, a world first, with its partners - April 28th, 2024
• BioSenic publishes on its website the restructuring plan submitted to the Enterprise Court of Nivelles - April 28th, 2024
• Sino Biological Finalizes the Acquisition of SignalChem Biotech, Strengthening Global Presence and Expanding Product Portfolio - April 28th, 2024
• Rakovina Therapeutics Inc. Announces 2023 Financial Results and Provides Corporate Update - April 28th, 2024
• Cronos Group Inc. to Hold Virtual 2024 Annual Meeting of Shareholders - April 28th, 2024
• Financière de Tubize - Dividend approval - April 28th, 2024
• Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant... - April 19th, 2024

Global News Feed Comments Off on Day One Reports First Quarter 2024 Financial Results and Corporate Progress | May 7th, 2024

About... Dr. Matthew Watson

Categories

• Bone Marrow Stem Cells (2,980)
• Cardiac Stem Cells (1,253)
• Global News Feed (2,975)
• Integrative Medicine (105)
• IPS Cell Therapy (459)
• Nano medicine (2)
• Regenerative Medicine (44)
• Skin Stem Cells (2,199)
• Spinal Cord Stem Cells (954)
• Stem Cell Therapy (528)

Archives

Recommended Sites

• California Stem Cell Research
• Cord Blood Banking
• Gene Therapy Breakthroughs
• Immortality Medicine
• Medical School Review
• Nano Technology American Physicians
• Videos Of Stem Cell Therapy